Patients who receive vascular grafts formed from polymer material such as Dacron® are required to take anti-coagulation drugs on a continuing basis to prevent blood clots. Why? What advances in such vascular implants are needed to make this precaution unnecessary?
We need at least 10 more requests to produce the solution.
0 / 10 have requested this problem solution
The more requests, the faster the answer.